GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » Earnings Yield %

GRI Bio (GRI Bio) Earnings Yield % : N/A% (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is GRI Bio Earnings Yield %?

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2024-05-16), the stock price of GRI Bio is $0.4007. GRI Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-25.20. Therefore, GRI Bio's earnings yield of today is N/A%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. GRI Bio's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


GRI Bio Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

GRI Bio's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=-25.200/0.4007
=N/A %

GRI Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.200 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.


GRI Bio  (NAS:GRI) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


GRI Bio Earnings Yield % Related Terms

Thank you for viewing the detailed overview of GRI Bio's Earnings Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


GRI Bio (GRI Bio) Business Description

Traded in Other Exchanges
N/A
Address
2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Executives
David Leslie Szekeres director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson director 20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro officer: Chief Medical Officer 828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz director, 10 percent owner, officer: Chief Executive Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi officer: Chief Scientific Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne director 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly officer: Chief Financial Officer C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell director 1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc. 10 percent owner 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren officer: SVP, Regul Affairs & Prog Mgmt C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi director C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer director, 10 percent owner C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon 10 percent owner SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052

GRI Bio (GRI Bio) Headlines

From GuruFocus

GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio

By Marketwired 06-27-2023